238 related articles for article (PubMed ID: 33409679)
1. Comparative analysis of polypoidal choroidal vasculopathy with and without hemorrhage treated by anti-VEGF monotherapy.
Iwasaki M; Kobayashi K; Aoki S; Miyamoto H; Imaizumi H
Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):1741-1750. PubMed ID: 33409679
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
3. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
6. THE INCIDENCE, CHARACTERISTICS, MANAGEMENT, PROGNOSIS, AND CLASSIFICATION OF BREAKTHROUGH VITREOUS HEMORRHAGE SECONDARY TO POLYPOIDAL CHOROIDAL VASCULOPATHY.
Zhao XY; Luo MY; Meng LH; Zhang WF; Li B; Wang EQ; Liu SZ; Yu WH; Chen YX
Retina; 2021 Aug; 41(8):1675-1685. PubMed ID: 33395221
[TBL] [Abstract][Full Text] [Related]
7. Current management strategy of polypoidal choroidal vasculopathy.
Ho CPS; Lai TYY
Indian J Ophthalmol; 2018 Dec; 66(12):1727-1735. PubMed ID: 30451173
[TBL] [Abstract][Full Text] [Related]
8. DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Chang YC; Cheng CK
Retina; 2020 Jul; 40(7):1403-1411. PubMed ID: 31181038
[TBL] [Abstract][Full Text] [Related]
9. MORPHOLOGIC FEATURES ASSOCIATED WITH FIBROTIC SCARRING AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY.
Kim JH; Chang YS; Kim JW; Kim CG; Lee DW; Kim YJ
Retina; 2018 Nov; 38(11):2168-2176. PubMed ID: 28930802
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197
[TBL] [Abstract][Full Text] [Related]
11. THE OCCURRENCE, CHARACTERISTICS, MANAGEMENT, AND PROGNOSIS OF RETINAL PIGMENT EPITHELIUM TEARS IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY: A Retrospective Study of 397 Patients.
Zhao XY; Xia S; Luo MY; Wang EQ; Chen YX
Retina; 2020 Mar; 40(3):477-489. PubMed ID: 30475788
[TBL] [Abstract][Full Text] [Related]
12. Polypoidal Choroidal Vasculopathy with Feeder Vessels: Characteristics, Fellow Eye Findings, and Long-term Treatment Outcomes.
Hwang HJ; Kim JH; Chang YS; Kim JW; Kim CG
Korean J Ophthalmol; 2017 Jun; 31(3):230-239. PubMed ID: 28534339
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
Singh SR; Sahoo NK; Goud NR; Chhablani J
Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of super stable polypoidal choroidal vasculopathy after initial remission with anti-VEGF monotherapy.
Choi S; Kang HM; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2021 Apr; 259(4):837-846. PubMed ID: 33245428
[TBL] [Abstract][Full Text] [Related]
15. Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Kokame GT; deCarlo TE; Kaneko KN; Omizo JN; Lian R
Ophthalmol Retina; 2019 Sep; 3(9):744-752. PubMed ID: 31511169
[TBL] [Abstract][Full Text] [Related]
16. Peripheral polypoidal choroidal vasculopathy as a cause of peripheral exudative hemorrhagic chorioretinopathy: a report of 10 eyes.
Goldman DR; Freund KB; McCannel CA; Sarraf D
Retina; 2013 Jan; 33(1):48-55. PubMed ID: 22836900
[TBL] [Abstract][Full Text] [Related]
17. [Polypoidal choroidal vasculopathy].
Yuzawa M
Nippon Ganka Gakkai Zasshi; 2012 Mar; 116(3):200-31; discussion 232. PubMed ID: 22568102
[TBL] [Abstract][Full Text] [Related]
18. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.
Koizumi H; Yamagishi T; Yamazaki T; Kinoshita S
Am J Ophthalmol; 2013 Feb; 155(2):305-313.e1. PubMed ID: 23022162
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
[TBL] [Abstract][Full Text] [Related]
20. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
Gemmy Cheung CM; Yeo I; Li X; Mathur R; Lee SY; Chan CM; Wong D; Wong TY
Am J Ophthalmol; 2013 Feb; 155(2):295-304.e1. PubMed ID: 23111181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
